DAratumumab and REvlimid REfractory MM

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Enrolling

Conditions: Multiple Myeloma

Study type: Observational

Funder types: Other

Identifiers

NCT06541860

DARE-MM

Details and patient eligibility

About

Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Phase I

• Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
• Patients aged ≥ 18 years
• Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data

Phase II

• Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
• Patients aged ≥ 18 years
• Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data

Exclusion criteria

• Patients not willing to consent to review of clinical data